Hussman Strategic Advisors Inc. Boosts Stock Position in Novavax, Inc. (NASDAQ:NVAX)

Hussman Strategic Advisors Inc. boosted its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 100.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,000 shares of the biopharmaceutical company's stock after buying an additional 84,000 shares during the period. Hussman Strategic Advisors Inc. owned 0.10% of Novavax worth $1,077,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Novavax during the 4th quarter valued at $27,000. New Age Alpha Advisors LLC purchased a new stake in shares of Novavax during the 4th quarter valued at $35,000. Kitching Partners LLC purchased a new stake in shares of Novavax during the 4th quarter valued at $89,000. Xponance Inc. purchased a new stake in shares of Novavax during the 4th quarter valued at $95,000. Finally, GAMMA Investing LLC increased its position in shares of Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 11,340 shares during the period. Hedge funds and other institutional investors own 53.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NVAX shares. B. Riley restated a "buy" rating on shares of Novavax in a research note on Monday, May 19th. Citigroup started coverage on Novavax in a research note on Tuesday, June 17th. They issued a "sell" rating and a $6.00 target price for the company. Finally, JPMorgan Chase & Co. reduced their target price on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research note on Friday, May 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Novavax presently has a consensus rating of "Hold" and a consensus price target of $17.00.

Novavax Price Performance

NVAX stock remained flat at $7.00 during trading on Friday. The company had a trading volume of 2,592,026 shares, compared to its average volume of 6,151,246. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $17.81. The stock has a market cap of $1.13 billion, a PE ratio of 2.64, a P/E/G ratio of 0.06 and a beta of 2.69. The business's fifty day moving average price is $6.88 and its 200-day moving average price is $7.37.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping the consensus estimate of $0.71 by $2.22. The business had revenue of $666.66 million for the quarter, compared to analysts' expectations of $204.08 million. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The business's revenue for the quarter was up 610.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.05) EPS. As a group, equities analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.